Tango Therapeutics Executive Compensation Details Released
Ticker: TNGX · Form: DEF 14A · Filed: Apr 21, 2025 · CIK: 1819133
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Tango Therapeutics DEF 14A shows exec comp details for 2023, focusing on equity awards for Adam Crystal & others.
AI Summary
Tango Therapeutics, Inc. filed a DEF 14A on April 21, 2025, detailing executive compensation for the fiscal year ending December 31, 2023. The filing includes information on equity awards granted to its principal executive officer, Adam Crystal, MD, PhD, and other non-principal executive officers. Specific details on the change in fair value of outstanding equity awards and year-end fair values are provided for the fiscal years 2022 and 2023.
Why It Matters
This filing provides transparency into how Tango Therapeutics compensates its top executives, which can influence investor perception and the company's ability to attract and retain talent.
Risk Assessment
Risk Level: low — This is a routine filing providing information on executive compensation and does not indicate any immediate financial distress or significant operational changes.
Key Numbers
- 2023 — Fiscal Year End (The primary period for which executive compensation data is detailed.)
- 2022 — Prior Fiscal Year (Used for comparative analysis of equity awards and their fair value changes.)
Key Players & Entities
- Tango Therapeutics, Inc. (company) — Filer of the DEF 14A
- Adam Crystal, MD, PhD (person) — Principal Executive Officer of Tango Therapeutics
- BCTG Acquisition Corp. (company) — Former name of Tango Therapeutics
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by companies to solicit proxies from shareholders for an upcoming annual or special meeting. It provides detailed information about matters to be voted on, including executive compensation, director elections, and other corporate governance issues.
Who is identified as the Principal Executive Officer (PEO) in this filing?
The filing identifies Adam Crystal, MD, PhD as the Principal Executive Officer (PEO) of Tango Therapeutics, Inc.
What types of compensation are detailed for the PEO and other executives?
The filing details equity awards, including stock options, and their associated fair values, changes in fair value, and year-end valuations for the fiscal years 2022 and 2023.
When was Tango Therapeutics, Inc. formerly known as BCTG Acquisition Corp.?
Tango Therapeutics, Inc. was formerly known as BCTG Acquisition Corp. prior to a name change on July 23, 2020.
What is the SIC code for Tango Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Tango Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 21, 2025 by Adam Crystal, MD, PhD regarding Tango Therapeutics, Inc. (TNGX).